Having trouble accessing articles? Reset your cache.

Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

Cell Design Lab successor Kyverna aims to expand T cell therapies to autoimmune diseases

The team behind Cell Design Labs and its acquirers at Gilead are looking to capitalize on their T cell engineering platform again, bringing it into new indications with the launch of Kyverna. The company is applying a set of T cell therapy technologies to autoimmune diseases, lending more support to the notion that T cell therapies have benefits beyond cancer.

Kyverna Therapeutics Inc. came out of stealth on Monday with a $25 million series A

Read the full 746 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE